Clinicn Investigator, Assc Prf Cancer Center, Mass General Research Institute

Associate Professor of Medicine Harvard Medical School

Associate Physician Medicine-Hematology and Medical Oncology, Massachusetts General Hospital

MD Tufts University School of Medicine 1978

alk; antineoplastic agents; antineoplastic combined chemotherapy protocols; benzenesulfonates; camptothecin; crizotinib; deoxycytidine; gastrointestinal malignancies; met; pancreatic neoplasms; pyridines; rectal neoplasms; ros1 The major area of my research focus is in the evaluation of new agents and approaches in phase I, pilot and early phase II trials. This includes the evaluation of pharmacokinetics and biological correlates of the activity of these agents or approaches. As an example, for the past 5 years, I have been working on evaluation of crizotinib as an ALK, ROS1, and MET inhibitor. I am also especially interested in the development of new theraputic approaches for gastrointestestional malignancies. I have an interest in designing and implementing systems to improve the quality and performance of clinical trials. This includes the development and utlization of computerized systems whenever possible. This involves close collaboration with a large group of individuals involved in the clinical research process.